Moreover, an attenuation of dyskinesia induced by long-term apomorphine was observed when the drug was administered in combination with an A2A antagonist [25], suggesting that A2A antagonists might lower the dyskinetic potential of dopamine-replacement therapy in specific conditions. The gene discussed is IGKV2D-29; the disease is drug-induced dyskinesia.